CSF2 and neoplasm: The local subcutaneous delivery of the cytokine adjuvant GM-CSF by encapsulated cells, together with irradiated autologous tumor cells, has been proposed for cancer immunotherapy and is currently under clinical evaluation (NCT02193503).62